Pieris Pharmaceuticals (NASDAQ:PIRS) Upgraded at StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a report published on Tuesday morning.

Pieris Pharmaceuticals Trading Up 0.4 %

PIRS opened at $16.07 on Tuesday. Pieris Pharmaceuticals has a twelve month low of $6.20 and a twelve month high of $22.32. The firm has a market capitalization of $21.21 million, a PE ratio of -1.33 and a beta of 0.66. The firm’s 50-day moving average price is $16.54 and its 200 day moving average price is $13.85.

Institutional Investors Weigh In On Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals makes up about 0.4% of BML Capital Management LLC’s portfolio, making the stock its 21st largest holding. BML Capital Management LLC owned approximately 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.